Axovant Sciences, with a high-profile Alzheimer’s treatment in Phase 3 studies, has brought on David Hung as CEO. Hung was founder, president, and CEO of San Francisco-based Medivation, which Pfizer (NYSE: PFE) bought for $14 billion last year, in large part to gain control of the prostate cancer drug enzalutamide (Xtandi).
Medivation’s Marion McCourt will also join Axovant (NYSE: AXON) as president and COO, and two former Medivation directors are joining the Axovant board. Axovant founding CEO Vivek Ramaswamy will continue to run Axovant’s parent company Roivant Sciences. Axovant’s Phase 3 MINDSET study is expected to release results in September, the company said.